zmax Drug Patent Profile

✉ Email this page to a colleague

When do Zmax patents expire, and when can generic versions of Zmax launch?

Zmax is a drug marketed by Pf Prism Cv and is included in one NDA. There are two patents protecting this drug.

This drug has fifty-one patent family members in forty-three countries.

The generic ingredient in ZMAX is azithromycin. There are thirty-two drug master file entries for this compound. Sixty-four suppliers are listed for this compound. Additional details are available on the azithromycin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zmax

A generic version of zmax was approved as azithromycin by PLIVA on November 14^th, 2005.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for zmax?
What are the global sales for zmax?
What is Average Wholesale Price for zmax?

Summary for zmax

International Patents:	51
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	74
Patent Applications:	3,137
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for zmax
What excipients (inactive ingredients) are in zmax?	zmax excipients list
DailyMed Link:	zmax at DailyMed

Drug patent expirations by year for zmax

US Patents and Regulatory Information for zmax

zmax is protected by two US patents.

Patents protecting zmax

Azithromycin dosage forms with reduced side effects
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BACTERIAL INFECTIONS

Multiparticulate crystalline drug compositions having controlled release profiles
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	ZMAX	azithromycin	FOR SUSPENSION, EXTENDED RELEASE;ORAL	050797-001	Jun 10, 2005		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Pf Prism Cv	ZMAX	azithromycin	FOR SUSPENSION, EXTENDED RELEASE;ORAL	050797-001	Jun 10, 2005		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for zmax

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	ZMAX	azithromycin	FOR SUSPENSION, EXTENDED RELEASE;ORAL	050797-001	Jun 10, 2005	⤷ Sign Up	⤷ Sign Up
Pf Prism Cv	ZMAX	azithromycin	FOR SUSPENSION, EXTENDED RELEASE;ORAL	050797-001	Jun 10, 2005	⤷ Sign Up	⤷ Sign Up
Pf Prism Cv	ZMAX	azithromycin	FOR SUSPENSION, EXTENDED RELEASE;ORAL	050797-001	Jun 10, 2005	⤷ Sign Up	⤷ Sign Up
Pf Prism Cv	ZMAX	azithromycin	FOR SUSPENSION, EXTENDED RELEASE;ORAL	050797-001	Jun 10, 2005	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for zmax

See the table below for patents covering zmax around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Norway	171556		⤷ Sign Up
Portugal	758244		⤷ Sign Up
African Regional IP Organization (ARIPO)	9500735		⤷ Sign Up
Canada	2467611	FORMES PHARMACEUTIQUES D'AZITHROMYCINE AYANT MOINS D'EFFETS SECONDAIRES (AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS)	⤷ Sign Up
Morocco	27848	FORMES POSOLOGIQUES D'AZITHROMYCINE A EFFETS SECONDAIRES REDUITS.	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for zmax

Patents protecting zmax

Make Better Decisions: Try a trial or see plans & pricing